Biocon Pharma gains tentative USFDA nod for Parkinson's disease capsules

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2025-12-06 06:00 GMT | Update On 2025-12-06 06:00 GMT

Bengaluru: Biocon has announced that Biocon Pharma Limited, a wholly owned subsidiary of the Company, has received tentative approval from the U.S Food and Drug Administration (U.S. FDA) for its abbreviated new drug application (ANDA) for Carbidopa and Levodopa Extended-Release Capsules, in 23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg, and 61.25 mg/245 mg strengths.

Carbidopa and Levodopa Extended-Release Capsules are indicated for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.

Parkinson disease is a brain condition that causes problems with movement, mental health, sleep, pain and other health issues. It gets worse over time. Common symptoms of the disease include tremors, painful muscle contractions and difficulty speaking.

Parkinson results in high rates of disability and the need for care. Many people with it also develop dementia.

The disease usually occurs in older people, but younger people can also be affected. Men are affected more often than women. The cause of the disease is unknown but people with a family history of the disease have a higher risk. Exposure to air pollution, pesticides and solvents may increase risk.

Biocon Limited, publicly listed in 2004, is a global biopharmaceutical company. It has developed and commercialized novel biologics, biosimilars and complex small molecule APIs in India and several key global markets, as well as generic formulations in the US and Europe.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Biocon Pharma gains tentative USFDA nod for Parkinson's disease capsules

Similar News

Senores Pharma gets Philippine FDA approval for basket of 10 products

Haryana Pharmacy Council to Deregister Pharmacists Over Illegal Sale of Psychotropic Drugs, MTP Kits

Semaglutide Patent Clash: Delhi HC Denies Novo Nordisk Injunction, Manufacturing by Dr Reddy's to Continue

Ipca Labs receives 3 USFDA observations for Tarapur facility

Bristol Myers Squibb Breyanzi approved by USFDA for adults with Marginal Zone Lymphoma

India renew Engagement Strategy with CEPI for cooperation on vaccine, allied technology RnD

Chhattisgarh clears over Rs 46 crore for new drug-testing lab and FDA building